Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Polycystic Ovary Syndrome 3Pituitary Neoplasms 3Prolactinoma 2Pituitary ACTH Hypersecretion 2Acromegaly 2Prostatic Neoplasms 1Ovarian Hyperstimulation Syndrome 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Heart Valve Diseases 1Dumping Syndrome 1Breast Neoplasms 1Brain Neoplasms 1ACTH-Secreting Pituitary Adenoma 1

Interventions

pasireotide 5Octreotide 4pegvisomant 2Cabergoline 2lanreotide 1Surgical Procedures, Operative 1Dosage Forms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Acromegaly × Cabergoline × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡